Discontinued — last reported Q3 '21
Products & Services · Deferred revenue, balance
License — Deferred revenue, balance
Neurocrine Biosciences License — Deferred revenue, balance decreased by 20.5% to $3.5M in Q3 2021 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryLiquidity
SignalHigher is better
VolatilityModerate
First reportedQ2 2021
Last reportedQ3 2021Nov 1, 2021
Rolls up toContract Liabilities
How to read this metric
A higher balance indicates significant upfront payments from new or existing collaborations that will be recognized in future periods, providing a buffer for future revenue.
Detailed definition
This metric represents the cumulative amount of payments received from licensing partners for which the associated perfo...
Peer comparison
Common in any industry with long-term service or licensing contracts where upfront payments are standard practice.
Metric ID:
nbix_segment_license_deferred_revenue_balanceHistorical Data
2 periods
| Q2 '21 | Q3 '21 | |
|---|---|---|
| Value | $4.4M | $3.5M |
| QoQ Change | — | -20.5% |
Range$3.5M – $4.4M
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's license — deferred revenue, balance?
- Neurocrine Biosciences (NBIX) reported license — deferred revenue, balance of $3.5M in Q3 2021.
- What does license — deferred revenue, balance mean?
- The portion of payments received from partners that has not yet been earned as revenue because the work is still in progress.